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http://dxObjective: Early injury is associated with the development of cardiac allograft vasculopathy in heart transplan-
tation. We examined whether adult heart transplant recipients surviving primary graft dysfunction were more
susceptible to the development of cardiac allograft vasculopathy than their nonprimary graft dysfunction coun-
terparts.
Methods: A total of 857 patients who underwent heart transplantation between January 1994 and December
2008 at our institution were reviewed. Primary graft dysfunction was defined as the need for extracorporeal
membrane oxygenation, open chest, or intra-aortic balloon pump placement within 72 hours of transplantation.
Cardiac allograft vasculopathy was defined as 50% coronary artery stenosis in any vessel. Allograft survival
was defined by patient death or need for retransplantation.
Results: Completed follow-up was available for 32 patients in the primary graft dysfunction group and 701 pa-
tients in the nonprimary graft dysfunction group. Mean recipient ages (56 years vs 55 years, respectively;
P ¼ .50) and ischemic times (220 minutes vs 208 minutes, respectively; P ¼ .35) were similar. Donor age
was significantly higher in the primary graft dysfunction group (38 years vs 32 years, P ¼ .02). Five-year sur-
vivals for the primary graft dysfunction and nonprimary graft dysfunction groups were 46.9% versus 78.9%
(P<.001). Conditional 5-year survivals in patients surviving the first year were 78.9% and 88.3% for the pri-
mary graft dysfunction and nonprimary graft dysfunction groups, respectively (P ¼ .18). Within a 30-day post-
operative period, there were more deaths in the primary graft dysfunction group (28.1% vs 2.3%, P<.0001) and
more retransplants (6.25% vs 0%, P ¼ .002). Of the patients surviving past 30 days, only 2 (8.7%) of the pri-
mary graft dysfunction patients developed cardiac allograft vasculopathy versus 144 (21.0%) in the nonprimary
graft dysfunction group (P<.001).
Conclusions: Primary graft dysfunction was associated with lower 30-day, 1-year, and 5-year allograft survival
rates. Surviving patients, however, did not show increased tendency toward cardiac allograft vasculopathy de-
velopment. (J Thorac Cardiovasc Surg 2013;145:869-73)Primary graft dysfunction (PGD) of heart allografts is
a condition in which the newly transplanted organ is unable
to meet the circulatory requirements of the recipient during
the peri- and postoperative periods as a result of left
ventricular, right ventricular, or biventricular dysfunction.1
Unlike lung transplantation, in which PGD was defined for-
mally and given a standard grading system in 2005 by an In-
ternational Society of Heart and Lung Transplantation
working group, PGD in heart transplantation has received
relatively little attention.2 Thus, despite being one of the
most common causes of 30-day mortality after heart trans-
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Xcurrently exists no widely accepted diagnostic criteria
or definition for the disorder.3,4 The causes of PGD are
not completely understood; however, intrinsic donor
organ abnormalities and recipient characteristics such
as pulmonary hypertension, inadequate donor heart
preservation, and/or nonspecific host-mediated inflamma-
tory injury are implicated.5
Although PGD affects early survival adversely, chronic
rejection known as cardiac allograft vasculopathy (CAV)
is the predominant limitation to survival in heart transplan-
tation beyond 1 year.6 Both immune- and nonimmune-
related factors remain associated with the development of
CAVand it is reasonable to hypothesize that the allograft in-
jury that leads to PGD in transplanted hearts will ultimately
place the organ at heightened risk for development of CAV
as well. This hypothesis is supported by abundant evidence
in the lung transplantation literature regarding the relation-
ship between PGD and the development of bronchiolitis ob-
literans syndrome, the corollary of chronic rejection in
pulmonary allografts.7-9 The causal relationship between
cardiac PGD and the development of CAV, however, has
yet to be clearly established.rdiovascular Surgery c Volume 145, Number 3 869
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XThe objective of this study is to discern whether patients
surviving PGD in heart transplantation are subsequently at
elevated risk for the development of CAV. In addition, we
compare long-term allograft function and survival in pa-
tients surviving PGD versus the non-PGD cohort.METHODS
The study was approved by the University of California at Los Angeles
(UCLA) institutional review board. A total of 857 patients transplanted at
UCLAMedical Center between January 1994 and December 2008 were re-
viewed retrospectively. Primary graft dysfunction was defined in patients
who required (1) extracorporeal membrane oxygenation (ECMO), (2)
open chest, and/or (3) usage of an intra-aortic balloon pump (IABP) within
72 hours of transplantation. Venoarterial ECMO was instituted via right
atrial and aortic cannulation either with or without concomitant open chest.
Patients who presented to the operating roomwith an IABP in place a priori
as a result of poor native heart function were excluded because the balloon
pumpswere removed on postoperative day 1 by protocol to avoid the risk of
bleeding during the immediate perioperative period and not because of the
specific needs of the new allograft. Patients with positive donor-specific an-
tibodies were excluded to remove hyperacute rejection as a potential cause
of early graft failure from this study.
Patients underwent annual coronary angiography as part of routine sur-
veillance after an initial baseline study around day 60 posttransplantation.
Cardiac allograft vasculopathy was defined as the presence of 50% ste-
nosis of 1 or more vessels. All donors older than the age of 40 years re-
ceived coronary angiograms as part of the initial evaluation, and the
presence of coronary artery disease excluded them from further consider-
ation for nonalternate list candidates. Allograft survival was examined at
30 days, 1 year, and 5 years posttransplantation and was defined as either
recipient death or the need for retransplantation. Donor and recipient
ages and ischemic times were documented. Patients were followed for an
average of 3.2 years after transplantation, with a range from 0 days to
13.2 years.
Continuous variables were reported as mean  standard deviation and
were compared with the Student t test. Categoric data were analyzed using
23 2 contingency tables, withP values determined by the Fisher exact test.
Mortality curves were established using Kaplan-Meier (actuarial) curves,
with P values generated by the log-rank test. Multivariable analyses were
performedwith the use of a proportional hazards regressionmodel for com-
peting risks. Two-tailed P values < .05 were considered statistically
significant.RESULTS
Of the 857 patients reviewed, 815 patients constituted the
non-PGD group and 42 were identified with PGD according
to the following criteria: 13 patients (30.9%) had institution
of ECMO, 23 patients (54.8%) had IABP, and 6 patients
(14.3%) were left with an open chest without concomitant
ECMO or IABP. Open chest was utilized in conjunction870 The Journal of Thoracic and Cardiovascular Surgwith 1 or both of the other therapeutic maneuvers as
follows: ECMOþIABP in 4 patients, ECMO alone in 1 pa-
tient, and IABP alone in 4 patients. These cases were clas-
sified either as ECMO in the first 2 categories and IABP in
the third group. A total of 610 of the non-PGD group and 30
of the PGD group were males (74.8% vs 71.4%, P ¼ .59).
The average recipient ages for the PGD and non-PGD
control groups were 56  13 years versus 55  13 years
(P¼ .50). The donor ages were 38 15 years versus 32
14 years (P ¼ .02) for the PGD and control groups, re-
spectively. Ischemic time was 220  85 minutes versus
208  66 minutes (P ¼ .35) for PGD and non-PGD cate-
gories. Table 1 shows the 3 variables in multivariable
analysis. When adjusting for recipient age and ischemic
time, there is a 2% increase in the odds of PGD for every
1-year increase in the donor age.
We have complete follow-up on 733 patients, of whom
701 are non-PGD patients and 32 are PGD patients. Of
the 23 PGD patients with allograft survival beyond 30
days, 2 developed CAV (8.7%) at an average time of 1.4
years posttransplant. Of the 684 non-PGD patients surviv-
ing past 30 days, 144 (21.0%) developed CAVat an average
of 4.4 years after transplantation. The difference in
incidence of CAV between the 2 groups is statistically
significant (P ¼ .02).
Figure 1 shows 5-year Kaplan-Meier survival curves for
both PGD and non-PGD groups, respectively. Five-year sur-
vival was 78.9% versus 46.9% in the non-PGD patients
versus PGD patients, respectively (P<.001). Correspond-
ing survival rates at 30 days and 1 year were 97.7% versus
89.4% and 87.5% versus 56.3%, respectively. Within the
immediate 30-day posttransplant period, 9 of 32 PGD pa-
tients expired compared with 16 of 701 in the control group
(28.1% vs 2.3%, P<.0001). Two of the primary graft dys-
function patients required retransplantation compared with
none in the control group (6.25% vs 0%, P ¼ .002).
Conditional survival curves past the first year shown in
Figure 2 were similar for both the PGD and non-PGD
groups, suggesting that patients who survived the initial in-
sult of PGD did not experience a worse long-term outcome
compared with their non-PGD counterparts (78.9% vs
88.3%, P ¼ .182).
DISCUSSION
Based on the hypothesis that early injury is associated
with the development of CAV in cardiac transplantation,
we examined whether adult heart transplant recipients sur-
viving PGD were more susceptible to the development of
CAV than their non-PGD counterparts. Although PGD in
lung transplantation has been strongly associated with
both diminished long-term survival as well as increased in-
cidence of bronchiolitis obliterans syndrome,7,10-13 the
corresponding issue in cardiac allografts has not received
similar scrutiny in the literature. There are no similarery c March 2013
TABLE 1. Multivariable analysis
Variable Odds ratio P value
Recipient age 1.00 .77
Donor age 1.02 .03
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FIGURE 2. Five-year conditional survival.CI, Confidence interval; PGD,
primary graft dysfunction.
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are in lungs, and the issue of long-term survival or develop-
ment of CAV has not been examined thoroughly. Although
some have attempted to look at overall survival of patients
with PGD managed with mechanical assist devices, they
found direct comparisons difficult because of the wide array
of definitions used by varying authors.14,15
The pulmonary allograft PGD classification system es-
tablished by the International Society of Heart and Lung
Transplantation in 2005 graded severity on a scale from
0 to 3 based on criteria of partial pressure of arterial oxygen
to inspired oxygen ratios (PAO2/FIO2) and infiltrates on chest
radiograph.2 The goals of standardizing taxonomy were
conducive to the multitude of studies examining the long-
term effects of lung allograft PGD by allowing for repro-
ducibility when discussing severity of the disease process.
Because no such classification system exists for heart trans-
plantation, we defined PGD by the following 3 criteria: (1)
need for ECMO, (2) need for IABP, and/or (3) need for an
open chest for decompression purposes within the first 72
hours posttransplantation. One could argue that the criteria
to determine PGD should include the necessity of high peri-
operative inotrope doses in addition to the mechanical cir-
culatory assist and open chest parameters used in this
study. The consistent documentation of inotrope dosage
and duration of therapy proved unreliable, however, with
patients from the earlier time points in this study. The cutoff
for high inotrope dosage is also arbitrary and there is as yet
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Xnumbers of inotropic agents, their dosage, or some combi-
nation of both the most relevant indicator of PGD of cardiac
allografts? A recent single-institution retrospective review
suggested 2 or more inotropic agents with high-dose norepi-
nephrine or epinephrine (either>0.07 mg/kg/min) as man-
datory criteria for PGD classification.4 Although the
authors are to be lauded for taking this first step, a consensus
working group opinion to define and categorize this disease
entity moving forward would be extremely useful.
The development of CAV is linked to immunologic and
nonimmunologic factors. Primary graft dysfunction can
theoretically exacerbate both etiologies through the upregu-
lation of cytokines, leading to activation of the cellular im-
mune system as well as localized inflammation leading to
endothelial injury.16 There is much work in animal models
regarding the link between inflammation and neointimal
hyperplasia characteristic of the CAV process.17-19 There
are many triggers of injury associated with PGD,
including oxidative stresses, insults of myocardial stretch
and/or dilation, catecholamine surges, and reactions to
foreign material associated with ECMO circuits and other
mechanical support devices. Left ventricular dysfunction
during the early postoperative period in heart
transplantation has indeed been found to correlate directly
to the loss of mean luminal diameter of coronary arteries,
indicative of greater CAV.20 Our data, paradoxically, dem-
onstrated a higher incidence of CAV in the non-PGD group.
An obvious explanation for this is that patients surviving
PGD are a self-selected group, and that the sickest patients
most affected by the process die early prior to the develop-
ment of CAV. Most of the mortality following cardiac PGD
is observed within the first postoperative month, as demon-
strated by the 29% 30-day mortality in this series. The lung
transplantation experience, however, is abundant with data
suggesting that although recipients with PGD have high up-
front mortality, surviving patients remain at heightened riskrdiovascular Surgery c Volume 145, Number 3 871
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Xfor the long-term development of bronchiolitis obliterans
and ultimate loss of graft and life.7,21,22 One factor that
may change the overall relationship between PGD and
CAV in heart transplant patients over time is the increased
success of mechanical circulatory support.1 It is quite pos-
sible that, as more patients survive the initial insult as a re-
sult of advances in ECMO circuit designs, centrifugal
pumps, as well as improved pharmacologic management,
overall CAV incidence will increase over time.
The adverse impact of donor ischemic time on higher
PGD rates is well accepted and reported in the literature.
One study demonstrated that an ischemic time>300 min-
utes lead to a 3-fold increase in PGD.23 These authors did
not, however, find that this translated into survival differ-
ences at either the 5- or 10-year time points, and they
did not look specifically at the issue of CAV development
in the prolonged ischemic time group. Another group
found ischemic time>240 minutes to be 1 of 6 indepen-
dent variables indicating higher risk for PGD, along with
recipient age 60 years, diabetes mellitus, inotrope ther-
apy, right atrial pressure 10 mm Hg, and donor age
30 years.4 Ischemic time in our series did not differ sig-
nificantly between the PGD and non-PGD groups. Our
median ischemic times were shorter than the previously
mentioned studies, however, and thus this variable may
not have contributed as significantly to the development
of PGD in our patient population. The availability of do-
nor organs in the Los Angeles metropolitan area may
have been a factor in this regard because it lowers overall
travel times for organ retrieval, keeping ischemic times
shorter.
Our data did emphasize the importance of donor age in
multivariable analysis when looking at the development
of PGD in newly transplanted hearts. Older donors have
also been implicated with poorer cardiac transplant out-
comes by other institutions. Causal factors cited include de-
creased ability towithstand longer ischemic times as well as
increased tendency toward CAV possibly because of preex-
isting coronary artery disease.24
In conclusion, PGD was associated with lower 30-day,
1-year, and 5-year survival rates. After the first year, how-
ever, there was no difference in survival between both cat-
egories, suggesting that mortality—when it occurs—is at
the earlier time points and conditional survival past 1 year
is the same. Although conclusions regarding CAV develop-
ment must be made carefully given the relatively low num-
ber of PGD patients in this series, those patients who
survived did not show an increased tendency toward CAV
development. These results may prove useful when coun-
seling patients surviving PGD with regard to their long-
term risks of developing chronic rejection in the form of
CAV and their overall survival in general. Unlike their
lung transplant counterparts, there are no data currently to872 The Journal of Thoracic and Cardiovascular Surgsuggest that they are at heightened risk of developing
chronic rejection over time.
Lastly, this study reiterates the need for formal clarifica-
tion and identification of cardiac allograft PGD by means of
a consensus group similar to that seen in lung transplanta-
tion. Only in this way will comparative multi-institutional
studies be enabled and can subsequent advances in the iden-
tification and treatment of PGD of cardiac allografts be
realized.
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